Homeopathic dilutions of TNF-alfa in psoriasis and rheumatoid arthritis

Alecu, Adrian; Gafitanu, Dumitru; Alecu, Mariana; Popa, Diana; Cridon, Ioana
July 2012
International Journal of High Dilution Resarch;2012, Vol. 11 Issue 40, p204
Academic Journal
Aim: Clinical and biological studies in the past years underlined the proinflammatory action of the citokine Tumoral Necrosis Factor in the pathophysiolology of psoriasis, psoriatic arthritis, rheumatoid arthritis. Knowing that the high dilution of substances can have an inverted effect, our hypotesis was that dillution made of TNF-alfa can decrease the clinical manifestation of such diseases. Materials and method: We included as a pilot group 10 patients presented in Lotus Life Integrative Medicine Center or Profamilia Medical Center Iasi with psoriasis and rheumatoid arthritis previously diagnosed by specialists, under speciality treatment with insufficient results and patients who deliberately expressed their preference for alternative treatment. We decided to exclude the patients which during the study could present aggravation of symptoms. The treatment protocol consisted in the administration under the tongue of the dilution of TNF-alfa 9CH in liquid form, 12 drops twice a day for at least 3 months. This was prepared diluting from Guna TNF-alfa 4CH in distiled water, completing with 30% of alcohol in the last solution. Patients under other medications continued to take their previous treatment unchanged. We called the patients for follow-up after 3 months. We took the written consent from the patients and the approval of the Ethical Committee of the University of Medicine and Pharmacy "Gr. T. Popa" of Iasi. Results: To analize the results we followed the subjective evolution of the patients, the total surface and thickness of eruptions in psoriasis patients and the pain intensity and stiffness in arthritis patients. Under this conditions, all the patients showed amelioration, with 2 out of 6 psoriasis patients showing complete clearance of eruptions. No patient reported adverse reactions during the treatment Conclusions: Even though the group of patients was small and not appropriate for statistical data the presence of a clinical response in all the patients and the absence of adverse reactions sustains the opportunity to extend the research on this subject.


Related Articles

  • Clinical and Ultrasound Examination of the Leeds Enthesitis Index in Psoriatic Arthritis and Rheumatoid Arthritis. Ibrahim, G.; Groves, C.; Chandramohan, M.; Beltran, A.; Valle, R.; Reyes, B.; Healy, P.; Harrison, A.; Helliwell, P. S. // ISRN Rheumatology;2011, Special section p1 

    Objective. To compare scores for the Leeds enthesitis index in psoriatic arthritis and rheumatoid arthritis using clinical assessment and ultrasonography (US). Design. Swelling and tenderness of the enthesis was assessed at six sites: lateral epicondyles of humerus (LE), medial condyles of femur...

  • Serum Levels of Hyaluronic Acid in Patients with Psoriatic Arthritis. Elkayam, O.; Yaron, I.; Shirazi, I.; Yaron, M.; Caspi, D. // Clinical Rheumatology;Nov2000, Vol. 19 Issue 6, p455 

    : The purpose of this study was to evaluate the serum levels of hyaluronic acid (HA) in a group of patients with psoriatic arthritis (PsA), with special emphasis on the relationships between HA levels and clinical parameters of joint and skin activity. Thirty-four patients with PsA, 34 patients...

  • Adalimumab in Psoriatic Arthritis. Mease, Philip // Drugs;2006, Vol. 66 Issue 11, p1497 

    The article reports on the psoriatic arthritis. The psoriatic arthritis is studied to occur in at least 30 percent of patients with psoriasis. The psoriatic arthritis is considered a milder version of rheumatoid arthritis. Disease-modifying drugs such as methotrexate and sulfasalazine in...

  • Adalimumab: hepatosplenic T-cell lymphoma.  // WHO Drug Information;2008, Vol. 22 Issue 3, p198 

    The article reports that the manufacturer of adalimumab is advising healthcare professionals of new safety information. It states that adalimumab is a tumor necrosis factor (TNF) alpha blocker authorized in adult patients for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing...

  • Miscellaneous.  // Current Medical Literature: Dermatology;2012, Vol. 17 Issue 1, p25 

    A review of the articles "Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis," by L. Bojke, "Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis," by D. H. Solomon and "The Ipswich Touch...

  • Tumor necrosis factor-α antagonists: Side effects and their management. Dogra, Sunil; Khullar, Geeti // Indian Journal of Dermatology, Venereology & Leprology;Jul2013 Supplement 1, Vol. 79, pS35 

    As elevated levels of tumor necrosis factor-alpha (TNF-α) are associated with disease severity in psoriasis and psoriatic arthritis, TNF-α antagonists are being used to treat moderate to severe disease in patients who have contraindications, fail to respond or develop side effects to...

  • Expanding the therapeutic options for psoriatic conditions. Lebwohl, Mark; Wong, Vicky Kwan; Della Croce, Christine // Patient Care for the Nurse Practitioner;Aug2007, Vol. 10 Issue 8, p17 

    The article reports that uses for relatively new biologic therapies approved for other conditions, such as rheumatoid arthritis, are now emerging for the treatment of moderate or severe chronic plaque psoriasis and psoriatic arthritis. It summarizes the major biologic agents as they gain FDA...

  • Administration of infliximab in general practitioners’ offices is safe. Stuby, Ulrike; Biesenbach, Georg; Pieringer, Herwig // Clinical Rheumatology;Nov2007, Vol. 26 Issue 11, p1863 

    Infliximab is used in the treatment of various diseases, such as rheumatoid arthritis (RA), psoriasis, psoriatic arthritis (PA), Crohn’s disease (CD) and ankylosing spondylitis (AS). In most countries, infliximab is given in hospitals or infusion centers, which are experienced in the...

  • Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis. Fattah, Nermeen S. A. Abdel; Hassan, Hanan E.; Galal, Zenab A.; El Okda, El Sayed E. // BMC Research Notes;2009, Vol. 2, p1 

    Background: Anti-cyclic citrullinated peptides (anti-CCP) are highly specific diagnostic and prognostic markers for rheumatoid arthritis (RA). They have been also found in psoriatic arthritis (PsA), with controversies as regards clinical and radiological associations. The current study assessed...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics